Empowering Ethiopia: Horizon Europe Grants €4M to Tackle Non-Communicable Diseases

By HEOR Staff Writer

August 17, 2023

The ENABLE research consortium has been awarded a generous €4 million grant from Horizon Europe to combat non-communicable diseases (NCDs) in Ethiopia.

The ENABLE consortium, a collaboration between the Norwegian Institute of Public Health (NIPH) and the Ethiopian Public Health Institute (EPHI), will kick off its mission in 2024 for a period of 4 years.

The project aims to establish a program, using evidence-based interventions, to promote healthy eating habits, increase physical activity, and reduce exposure to pollution within urban communities in Ethiopia.

This initiative will be delivered across four Ethiopian cities: Addis Ababa, Adama, Harar, and Jimma, targeting pregnant women and their children in particular.

This is a prime example of how combining public health, healthcare access, and environmental health, supported by digital tools, can significantly improve a population’s health.

This project aligns with Ethiopia’s National NCD prevention strategy and contributes to closing the global knowledge gap for implementing evidence-based interventions.

The team is led by Dr Eleni Papadopoulou (NIPH) and Dr Masresha Tessema (EPHI) as they embark on this vital mission.

Reference url

Recent Posts

Strengthening Supply Chains: The EU Critical Medicines Act

By João L. Carapinha

May 12, 2026

The European Medicines Agency (EMA) has welcomed the provisional political agreement on the EU Critical Medicines Act, an initiative designed to enhance the availability, production, and supply of critical medicines throughout the European Union. This agreement represents a key a...
Johnson & Johnson Advances Neuropsychiatry Treatment Innovations at APA and ASCP Conferences

By HEOR Staff Writer

Neuropsychiatry treatment innovations continue to reshape care for complex conditions. At the recent APA and ASCP meetings, Johnson & Johnson presented new portfolio and pipeline data focused on major depressive disorder, treatment-resistant depression, and schizophrenia — offering p...
Marstacimab Cost-Effectiveness Analysis in Hemophilia Treatment: A Portuguese Assessment

By HEOR Staff Writer

The public assessment report for Hympavzi (marstacimab) in Portugal concludes that the product offers no added therapeutic value relative to recombinant factor VIII concentrates and emicizumab in patients aged 12 years and older weighing at least 35 kg with severe hemophilia A without factor VIII...